EVIDENCE PROFILE / PUBLISHED
Sermorelin
Sermorelin is an amidated 29-amino-acid GHRH fragment; acetate and delivery formulation remain part of product identity. Small physiology studies report acute GH responses. Historical therapeutic evidence was tied to Geref and a narrow pediatric population.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. It stimulates pituitary growth-hormone release and has been used in diagnostic and pediatric growth research.
Identity
Sermorelin is an amidated 29-amino-acid GHRH fragment; acetate and delivery formulation remain part of product identity.
Biological mechanism or research interest
It stimulates pituitary growth-hormone release and has been used in diagnostic and pediatric growth research.
Verified approved human uses
FDA records show historical Geref approvals, including a pediatric short-stature population selected by growth-hormone testing. The reviewed 2024 FDA briefing treats that approval as historical; it does not approve a current catalogue vial or adult anti-aging use.
Investigational human evidence
Small physiology studies report acute GH responses. Historical therapeutic evidence was tied to Geref and a narrow pediatric population.
Popular claims versus demonstrated findings
Adult wellness, sleep, fat-loss, muscle, and anti-aging claims are not supported by the historical pediatric indication.
Human versus animal or cell evidence
GHRH receptor pharmacology establishes a hormone signal, not a patient-important outcome.
Limitations and known risks
Endocrine effects, glucose changes, intracranial or neoplastic concerns, formulation quality, and long-term use require product-specific assessment.
